Baseline information of the patients with AOSD with MAS at enrollment
| No. . | Sex . | Age (y) . | Disease duration (mo) . | Previous treatments . | Last regimen before ruxolitinib . | Treatments after enrollment . | Follow-up (mo) . | Clinical evaluation . | Present pred dose (mg/d) . | RNA-seq . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 40 | 4 | Pred, CsA, VP16 | Pred | Pred 130 mg + ruxolitinib 10 mg twice daily | 12 | CR | 5 | Y |
| 2 | F | 64 | 35 | Pred, CsA, tofacitinib, VP16 | Pred + VP16 + CsA | Pred 65 mg + ruxolitinib 10 mg twice daily | 15 | CR | 5 | Y |
| 3 | F | 42 | 1 | Pred, CsA | Pred + VP16 + CsA | Pred 60 mg + CsA + ruxolitinib 10 mg twice daily | 15 | CR | 5 | N |
| 4 | F | 22 | 41 | Pred, CsA, LEF, tofacitinib, HCQ | Pred + VP16 + HCQ | Pred 300 mg + CsA + ruxolitinib 5 mg twice daily | 8 | CR | 12.5 | Y |
| 5 | F | 57 | 29 | Pred, HCQ, MTX | Pred + VP16 | Pred 260 mg + ruxolitinib 10 mg twice daily | 3 | CR | 40 | N |
| 6 | F | 43 | 1 | Pred, baricitinib, VP16, HCQ, tocilizumab | Pred + CsA + VP16 | Pred 50 mg + CsA + ruxolitinib 5 mg twice daily | 3 | PR | 25 | N |
| 7 | F | 40 | 5 | Pred, CsA, VP16 | Pred | Pred 200 mg + ruxolitinib 5 mg twice daily | 12 | Relapse at 8 months | 5 | N |
| 8 | F | 30 | 120 | Pred | Pred + VP16 | Pred 60 mg + CsA + ruxolitinib 5 mg twice daily | 10 | CR | 2.5 | N |
| 9 | F | 37 | 6 | Pred, baricitinib, VP16, HCQ, tocilizumab | Pred + CsA + VP16 | Pred 50 mg + CsA + ruxolitinib 5 mg twice daily | 4 | CR | 20 | N |
| 10 | F | 29 | 25 | Pred, MTX, tofacitinib, HCQ | Pred + CsA + VP16 | Pred 50 mg + CsA + ruxolitinib 5 mg twice daily | 12 | CR | 5 | N |
| No. . | Sex . | Age (y) . | Disease duration (mo) . | Previous treatments . | Last regimen before ruxolitinib . | Treatments after enrollment . | Follow-up (mo) . | Clinical evaluation . | Present pred dose (mg/d) . | RNA-seq . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 40 | 4 | Pred, CsA, VP16 | Pred | Pred 130 mg + ruxolitinib 10 mg twice daily | 12 | CR | 5 | Y |
| 2 | F | 64 | 35 | Pred, CsA, tofacitinib, VP16 | Pred + VP16 + CsA | Pred 65 mg + ruxolitinib 10 mg twice daily | 15 | CR | 5 | Y |
| 3 | F | 42 | 1 | Pred, CsA | Pred + VP16 + CsA | Pred 60 mg + CsA + ruxolitinib 10 mg twice daily | 15 | CR | 5 | N |
| 4 | F | 22 | 41 | Pred, CsA, LEF, tofacitinib, HCQ | Pred + VP16 + HCQ | Pred 300 mg + CsA + ruxolitinib 5 mg twice daily | 8 | CR | 12.5 | Y |
| 5 | F | 57 | 29 | Pred, HCQ, MTX | Pred + VP16 | Pred 260 mg + ruxolitinib 10 mg twice daily | 3 | CR | 40 | N |
| 6 | F | 43 | 1 | Pred, baricitinib, VP16, HCQ, tocilizumab | Pred + CsA + VP16 | Pred 50 mg + CsA + ruxolitinib 5 mg twice daily | 3 | PR | 25 | N |
| 7 | F | 40 | 5 | Pred, CsA, VP16 | Pred | Pred 200 mg + ruxolitinib 5 mg twice daily | 12 | Relapse at 8 months | 5 | N |
| 8 | F | 30 | 120 | Pred | Pred + VP16 | Pred 60 mg + CsA + ruxolitinib 5 mg twice daily | 10 | CR | 2.5 | N |
| 9 | F | 37 | 6 | Pred, baricitinib, VP16, HCQ, tocilizumab | Pred + CsA + VP16 | Pred 50 mg + CsA + ruxolitinib 5 mg twice daily | 4 | CR | 20 | N |
| 10 | F | 29 | 25 | Pred, MTX, tofacitinib, HCQ | Pred + CsA + VP16 | Pred 50 mg + CsA + ruxolitinib 5 mg twice daily | 12 | CR | 5 | N |
CsA, cyclosporine A; F, female; HCQ, hydroxychloroquine; LEF, leflunomide; M, male; N, no; MTX, methotrexate; Pred, prednisone; VP16, etoposide; Y, yes.